{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023095","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2026-05-14T20:15:44+00:00","discovered_at":"2026-05-14T20:18:00.261608+00:00","generated_at":"2026-05-14T20:51:33.443077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance","bullets":["Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.","Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.","Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.","Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.","Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023095","json":"https://secwatch.observer/filing/0001493152-26-023095.json","markdown":"https://secwatch.observer/filing/0001493152-26-023095.md","text":"https://secwatch.observer/filing/0001493152-26-023095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/0001493152-26-023095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:51:33.443077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a191e709eb2f2657fac2a93bffc9185538edc0bd","claim":"INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2026 results: revenue $9.0 million, net income $0.8 million. Guidance reaffirmed.","evidence_excerpt":"Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/0001493152-26-023095-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$9.0 million"},{"label":"Net income","value":"$0.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}